Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2000

View Archived Issues

Protein Design Labs enters patent license agreement with Merck KGaA

Vertex enters genomic and proteomic alliance with Harvard

Immunomedics overviews product pipeline

Inflazyme reports phase I results with IPL-576092; phase II to commence mid-year

Alteon initiates phase IIa clinical trial of ALT-711

U.S. and Brazilian researchers team up to design new ribonucleotide reductase inhibitors

Patient dosing begins in phase I clinical trial of Angiostatin protein

Anxiolytic-like effects demonstrated for human ORL1 receptor agonist

Medivir completes acquisition of Mimetrix

Novel copolymer adjuvant enhances flu vaccine efficacy and immunogenicity

Inhibitors of IL-5 production synthesized by Janssen

Vanguard Medica highlights product development efforts for year-end 1999

Pola focuses on development of antifungal agents

Japanese patent issued to Sumitomo for new ECE inhibitors

Novel DELTA-lactones with utility in inflammatory conditions disclosed by Inflazyme

Proteasome inhibitor proven to induce apoptosis and to exert antitumor activity in vivo

New hybrid polar differentiation-inducing agent pyroxamide progresses to clinical trials

Maxamine plus IFN-alpha yields up to 69% complete response in HCV

Enbrel recommended by FDA advisory committee for early RA

Japanese academic team describes new anticancer compound

Novel antimalarial drug candidate presented at scientific meeting

News from FASEB: TBC-1269 mechanism-of-action studies described

Novel method of controlling hypertension described at Experimental Biology

Opioid agonists for the prevention of myocardial ischemia

British investigators implicate endothelin in the pathophysiology of BPH

Bayer reports continued success in clinical studies evaluating Bay-38-9456 for ED

Potential antiatherogenic agent featured in two presentations at Experimental Biology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...